Nursing Department, The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU), No.88 Jiefang road, Shangcheng District, Hangzhou, 310009, Zhejiang Province, China.
Zhejiang University City College, No. 51 Huzhou Street, Gongshu District, Hangzhou, 310015, Zhejiang Province, China.
BMC Public Health. 2022 Aug 24;22(1):1608. doi: 10.1186/s12889-022-13995-z.
There is an increasing prevalence of cardiovascular disease (CVD) in China, which represents the leading cause of mortality. Precise CVD risk identification is the fundamental prevention component. This study sought to systematically review the CVD risk prediction models derived and/or validated in the Chinese population to promote primary CVD prevention.
Reports were included if they derived or validated one or more CVD risk prediction models in the Chinese population. PubMed, Embase, CINAHL, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), VIP database, etc., were searched. The risk of bias was assessed with the Prediction Model Risk of Bias Assessment Tool (PROBAST). Meta-analysis was performed in R using the package metamisc.
From 55,183 records, 22 studies were included. Twelve studies derived 18 CVD risk prediction models, of which seven models were derived based on a multicentre cohort including more than two provinces of mainland China, and one was a model developed based on a New Zealand cohort including Chinese individuals. The number of predictors ranged from 6 to 22. The definitions of predicted outcomes showed considerable heterogeneity. Fourteen articles described 29 validations of 8 models. The Framingham model and pooled cohort equations (PCEs) are the most frequently validated foreign tools. Discrimination was acceptable and similar for men and women among models (0.60-0.83). The calibration estimates changed substantially from one population to another. Prediction for atherosclerotic cardiovascular disease Risk in China (China-PAR) showed good calibration [observed/expected events ratio = 0.99, 95% PI (0.57,1.70)] and female sex [1.10, 95% PI (0.23,5.16)].
Several models have been developed or validated in the Chinese population. The usefulness of most of the models remains unclear due to incomplete external validation and head-to-head comparison. Future research should focus on externally validating or tailoring these models to local settings.
This systematic review was registered at PROSPERO (International Prospective Register of Systematic Reviews, CRD42021277453).
中国心血管疾病(CVD)的患病率不断上升,它是导致死亡的主要原因。准确识别 CVD 风险是基本的预防措施。本研究旨在系统回顾在中国人群中得出和/或验证的 CVD 风险预测模型,以促进一级 CVD 预防。
如果报告在中国人群中得出或验证了一个或多个 CVD 风险预测模型,则将其纳入。检索了 PubMed、Embase、CINAHL、Web of Science、Scopus、中国国家知识基础设施(CNKI)、维普数据库等。使用预测模型风险偏倚评估工具(PROBAST)评估风险偏倚。使用 R 中的 package metamisc 进行 meta 分析。
从 55183 条记录中,纳入了 22 项研究。12 项研究得出了 18 个 CVD 风险预测模型,其中 7 个模型是基于包括中国大陆两个以上省份的多中心队列得出的,1 个模型是基于包括新西兰的中国个体的队列得出的。预测指标的数量从 6 到 22 不等。预测结果的定义存在相当大的异质性。14 篇文章描述了 8 个模型的 29 次验证。Framingham 模型和汇总队列方程(PCE)是最常验证的国外工具。模型在男性和女性中的区分度均在可接受范围内(0.60-0.83)。校准估计值在不同人群中变化很大。在中国动脉粥样硬化性心血管疾病风险预测(China-PAR)中,校准良好[观察/预期事件比=0.99,95%置信区间(0.57,1.70)],女性[1.10,95%置信区间(0.23,5.16)]。
中国人群中已经开发或验证了多个模型。由于外部验证不完整和头对头比较,大多数模型的有用性仍不清楚。未来的研究应集中于对这些模型进行外部验证或适应当地情况。
本系统评价在 PROSPERO(国际前瞻性系统评价注册库,CRD42021277453)中进行了注册。